U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336797) titled 'Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy' on Nov. 20, 2025.
Brief Summary: We investigate the role of empagliflozin in the treatment of obesity in PLWH.
Study Start Date: Sept. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Metabolic Syndrome
Obesity & Overweight
HIV (Human Immunodeficiency Virus)
Intervention:
DRUG: Empagliflozin (oral)
Empagliflozin is an oral medication used primarily to treat type 2 diabetes. It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors). Empagliflozin blocks SGLT2 proteins in the kidn...